JP Morgan Chase
CTNM

JP Morgan Chase’s Contineum Therapeutics CTNM Stock Holding History

JP Morgan Chase’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31K Buy
2,488
+696
+39% +$9.34K ﹤0.01% 6379
2025
Q4 		$20.5K Buy
+1,792
New +$20.4K ﹤0.01% 6496
2025
Q3 		– Sell
-1,108
Closed -$4.4K – 7779
2025
Q2 		$4.4K Sell
1,108
-4,059
-79% -$17.6K ﹤0.01% 6432
2025
Q1 		$36.1K Sell
5,167
-23,259
-82% -$212K ﹤0.01% 5977
2024
Q4 		$416K Buy
28,426
+25,934
+1,041% +$411K ﹤0.01% 5139
2024
Q3 		$47.7K Sell
2,492
-466
-16% -$8.94K ﹤0.01% 6009
2024
Q2 		$52.1K Buy
+2,958
New +$47.6K ﹤0.01% 5843

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's CTNM Position: Q1 2026 in Review

JP Morgan Chase increased its Contineum Therapeutics (CTNM) stake by 39% in Q1 2026, buying an estimated $9.34K and bringing the position to 2,488 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #6379.

JP Morgan Chase first reported a position in CTNM in Q2 2024 and has held it in 7 quarters since. The position peaked at $416K in Q4 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • JP Morgan Chase held 2,488 shares of Contineum Therapeutics worth $31K as of Q1 2026.
  • JP Morgan Chase bought 696 Contineum Therapeutics shares in Q1 2026, an estimated $9.34K.
  • Contineum Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6379 holding.
  • JP Morgan Chase first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's Contineum Therapeutics position peaked at $416K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.